3oyp
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | [[ | + | ==HCV NS3/4A in complex with ligand 3== |
+ | <StructureSection load='3oyp' size='340' side='right' caption='[[3oyp]], [[Resolution|resolution]] 2.76Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[3oyp]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Hepatitis_c_virus_(isolate_japanese) Hepatitis c virus (isolate japanese)]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3OYP OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3OYP FirstGlance]. <br> | ||
+ | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | ||
+ | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=0Y8:(4R)-4-[(7-BROMOISOQUINOLIN-1-YL)OXY]-L-PROLINE'>0Y8</scene>, <scene name='pdbligand=0Y9:(1R,2S)-1-AMINO-2-ETHENYLCYCLOPROPANECARBOXYLIC+ACID'>0Y9</scene>, <scene name='pdbligand=0YA:CYCLOPROPANESULFONAMIDE'>0YA</scene>, <scene name='pdbligand=DAL:D-ALANINE'>DAL</scene>, <scene name='pdbligand=PPI:PROPANOIC+ACID'>PPI</scene></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3oyp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3oyp OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3oyp RCSB], [http://www.ebi.ac.uk/pdbsum/3oyp PDBsum]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Designing selective inhibitors of proteases has proven problematic, in part because pharmacophores that confer potency exploit the conserved catalytic apparatus. We developed a fundamentally different approach by designing irreversible inhibitors that target noncatalytic cysteines that are structurally unique to a target in a protein family. We have successfully applied this approach to the important therapeutic target HCV protease, which has broad implications for the design of other selective protease inhibitors. | ||
- | + | Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine.,Hagel M, Niu D, St Martin T, Sheets MP, Qiao L, Bernard H, Karp RM, Zhu Z, Labenski MT, Chaturvedi P, Nacht M, Westlin WF, Petter RC, Singh J Nat Chem Biol. 2011 Jan;7(1):22-4. Epub 2010 Nov 28. PMID:21113170<ref>PMID:21113170</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | </div> | |
- | + | == References == | |
- | + | <references/> | |
- | + | __TOC__ | |
- | + | </StructureSection> | |
- | + | [[Category: Bernard, H]] | |
- | == | + | [[Category: Chaturvedi, P C]] |
- | < | + | [[Category: Hagel, M]] |
- | [[Category: Bernard, H | + | [[Category: Karp, R M]] |
- | [[Category: Chaturvedi, P C | + | [[Category: Labenski, M T]] |
- | [[Category: Hagel, M | + | [[Category: Martin, T St]] |
- | [[Category: Karp, R M | + | [[Category: Nacht, M]] |
- | [[Category: Labenski, M T | + | [[Category: Niu, D]] |
- | [[Category: Martin, T St | + | [[Category: Petter, R C]] |
- | [[Category: Nacht, M | + | [[Category: Qiao, L]] |
- | [[Category: Niu, D | + | [[Category: Sheets, M P]] |
- | [[Category: Petter, R C | + | [[Category: Singh, J]] |
- | [[Category: Qiao, L | + | [[Category: Westlin, W F]] |
- | [[Category: Sheets, M P | + | [[Category: Zhu, Z]] |
- | [[Category: Singh, J | + | |
- | [[Category: Westlin, W F | + | |
- | [[Category: Zhu, Z | + | |
[[Category: Hepatitis c virus]] | [[Category: Hepatitis c virus]] | ||
[[Category: Hydrolase-hydrolase inhibitor complex]] | [[Category: Hydrolase-hydrolase inhibitor complex]] |
Revision as of 12:14, 9 December 2014
HCV NS3/4A in complex with ligand 3
|
Categories: Bernard, H | Chaturvedi, P C | Hagel, M | Karp, R M | Labenski, M T | Martin, T St | Nacht, M | Niu, D | Petter, R C | Qiao, L | Sheets, M P | Singh, J | Westlin, W F | Zhu, Z | Hepatitis c virus | Hydrolase-hydrolase inhibitor complex | Ns3 | Ns4a | Protease inhibition | Serine protease